Literature DB >> 1647198

Cytoplasmic juxtamembrane region of the insulin receptor: a critical role in ATP binding, endogenous substrate phosphorylation, and insulin-stimulated bioeffects in CHO cells.

J M Backer1, G G Schroeder, D A Cahill, A Ullrich, K Siddle, M F White.   

Abstract

We have expressed in CHO cells a mutant receptor (IR delta 960) from which 12 amino acids in the juxtamembrane region (A954-D965), including Tyr960, have been deleted. The mutant receptor bound insulin normally but exhibited an increased Km for ATP during autophosphorylation. Upon prolonged incubation in vitro, or at high ATP concentrations such as those observed in vivo, autophosphorylation of IR delta 960 was similar to wild type, and the in vitro phosphotransferase activity of the autophosphorylated IR delta 960 was normal. These results suggest that the deletion did not cause a nonspecific structural disruption of the catalytic domain of IR delta 960. In vivo autophosphorylation of the IR delta 960 receptor was reduced by 30% after 2 min of insulin stimulation and was similar to the wild-type receptor after 30 min of insulin stimulation. However, the mutant receptor was defective in insulin-stimulated tyrosyl phosphorylation of the endogenous substrate pp185. In addition, IR delta 960 was deficient in mediating insulin stimulation of glycogen and DNA synthesis. Thus, autophosphorylation of the insulin receptor is necessary but not sufficient for signal transmission. These data extend the hypothesis that the cytoplasmic juxtamembrane region of the insulin receptor is important for its interactions with ATP, intracellular substrates, and other proteins and is broadly necessary for biological signal transmission.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647198     DOI: 10.1021/bi00240a003

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

Review 1.  Role of binding proteins to IRS-1 in insulin signalling.

Authors:  W Ogawa; T Matozaki; M Kasuga
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

2.  Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells.

Authors:  C H Lee; W Li; R Nishimura; M Zhou; A G Batzer; M G Myers; M F White; J Schlessinger; E Y Skolnik
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

3.  Common elements in interleukin 4 and insulin signaling pathways in factor-dependent hematopoietic cells.

Authors:  L M Wang; A D Keegan; W Li; G E Lienhard; S Pacini; J S Gutkind; M G Myers; X J Sun; M F White; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

4.  Distinctive effects of the carboxyl-terminal sequence of the insulin-like growth factor I receptor on its signaling functions.

Authors:  D Liu; C S Zong; L H Wang
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

5.  Insulin inhibition of protein degradation in cells expressing wild-type and mutant insulin receptors.

Authors:  F G Hamel; J Fawcett; C I Andersen; P Berhanu; R G Bennett; W C Duckworth
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

6.  Insulin receptor substrate 1 rescues insulin action in CHO cells expressing mutant insulin receptors that lack a juxtamembrane NPXY motif.

Authors:  D Chen; D J Van Horn; M F White; J M Backer
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

7.  Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation.

Authors:  J M Backer; M G Myers; S E Shoelson; D J Chin; X J Sun; M Miralpeix; P Hu; B Margolis; E Y Skolnik; J Schlessinger
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

8.  The insulin receptor juxtamembrane region contains two independent tyrosine/beta-turn internalization signals.

Authors:  J M Backer; S E Shoelson; M A Weiss; Q X Hua; R B Cheatham; E Haring; D C Cahill; M F White
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.